Participants receiving any medications or substances that are strong inhibitors or inducers of CYP3A4/5 are ineligible; the required washout period prior to starting treatment is 2 weeks for CYP3A inhibitors, 3 weeks for CYP3A inducers, and 5 weeks for enzalutamide; dihydropyridine calcium-channel blockers are permitted for management of hypertension
The following medications or non-drug therapies are also prohibited while on treatment in this study:\r\n* Other anti-cancer therapies\r\n* Other investigational drugs\r\n* Patients taking any medications or substances that are strong inhibitors or inducers of CYP3A or CYP2C8 are ineligible
Patients receiving any medications or substances that are potent inhibitors or inducers of
Patients receiving any medications or substances that are strong inhibitors of CYP450 3A4 isoenzyme are ineligible; patients must be off the strong inhibitor for at least 1 week prior to being deemed eligible
Receiving any medications or substances that are inducers of CYP3A4; use of inducers are prohibited =< 7 days prior to randomization
Participants receiving any medications or substances that are moderate or strong inhibitors or inducers of CYP3A isoenzymes are ineligible; lists including medications and substances known or with the potential to interact with the CYP3A isoenzymes
Patients who require concurrent treatment with any medications or substances that are potent inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) are ineligible
Receiving any medications or substances that are potent inhibitors or inducers of CYP3A isoenzymes within 7 days prior to registration
Receiving any medications or substances which in the opinion of the investigators would interfere with treatment; examples could include strong inhibitors of CYP3A4 at oncologist discretion
Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 complex. Lists including medications and substances known or with the potential to interact with the CYP3A4 isoenzymes
Patients receiving any medications or substances that are strong inhibitors and/or strong or moderate inducers of CYP3A4 are ineligible
Patients receiving any medications or substances that are moderate to strong inhibitors CYP1A2 are ineligible
Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible
Patients receiving any medications or substances that are potent inhibitors or inducers of CYP1A2 or CYP2D6 are ineligible
Patients receiving any medications or substances that are strong inhibitors or inducers of CYP1A2 and/or CYP3A4 are ineligible
PHASE I AND II SCLC AND UROTHELIAL CARCINOMA EXPANSION COHORT: Patients receiving any medications or substances that are strong and moderate inhibitors or inducers of cytochrome P450, family 3, subfamily A (CYP3A) are ineligible
mCRPC EXPANSION COHORT: Patients receiving any medications or substances that are strong and moderate inhibitors or inducers of CYP3A are ineligible
Subjects requiring any medications or substances that are strong inhibitors or inducers of CYP3A during the course of the study are ineligible
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nPatients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible; dihydropyridine calcium-channel blockers are permitted for management of hypertension
PHASE II STUDY COHORT 5 TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nPatients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible; dihydropyridine calcium-channel blockers are permitted for management of hypertension
PHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nPatients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible; dihydropyridine calcium-channel blockers are permitted for management of hypertension
Receiving any medications or substances that are inducers of CYP3A4; use of inducers are prohibited =< 7 days prior to registration
Participants receiving any medications or substances that are potent inhibitors of CYP3A4, including grapefruit juice are ineligible; participants receiving fluconazole are also ineligible
Patients receiving any medications or substances that are substrates, inducers, or inhibitors of cytochrome P450 2C9 (CYP2C9) enzyme
TREATMENT: Eligibility of subjects receiving any medications or substances known to affect or with the potential to affect the activity or pharmacokinetics (i.e., cytochrome P450, family 3, subfamily A, polypeptide 4 [CYP450], P-glycoprotein [PgP]) of any of the study drugs will be determined following review of their cases by the principal investigator (PI); patients on strong and moderate cytochrome P450 system inducers or inhibitors are ineligible; every effort would be made to switch patients off medications that are known substrates of CYP450; if it is medically important for the patient to remain on such medications, these patients can still be eligible to participate based on PI discretion
DOSE ESCALATION COHORT: Current use or anticipated need for treatment with any medications or substances that are inhibitors or inducers of CYP3A4
DOSE EXPANSION COHORT: Current use or anticipated need for treatment with any medications or substances that are inhibitors or inducers of CYP3A4
Patients receiving any medications or substances that are potent inhibitors or inducers of CYP3A4 are ineligible; the required washout period for strong inhibitors is 2 weeks and at least one week for moderate inhibitors; the required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 4 weeks for other agents
Patients who need chronic use of medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible
Participants receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible\r\n* Strong inhibitors and inducers of UGT/PgP should be used with caution
Patients receiving any medications or substances to treat active infection
Concurrent use of medications or substances that are strong inhibitors of CY3A4 are ineligible
Receiving any medications or substances that are inducers of cytochrome CYP450 2C8; use of the following inducers is prohibited =< 7 days prior to registration\r\n* Inducer of CYP2C8: rifampin
Receiving any medications or substances that are inducers of CYP450 2C9; use of the following inducers is prohibited =< 7 days prior to registration\r\n* Inducers of CYP2C9: rifampin, secobarbital
PHASE II: Patients must NOT be taking current medications or substances that are inhibitors or inducers of CYP3A4
Patients who require prohibited medications with potential for serious interactions with protocol therapy, and who cannot have therapeutic substitution are excluded; patients receiving any medications or substances that are inhibitors or inducers of cytochrome P450 (CYP450) enzyme(s) are ineligible
Because MK-2206 is metabolized primarily by the cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) liver enzyme, the eligibility of patients taking medications that are potent inducers or inhibitors of that enzyme will be determined following a review of their case by the principal investigator; every effort should be made to switch patients taking such agents or substances to other medications
Participants receiving any medications or substances that are strong inhibitors or inducers of cytochrome P450, family 3, subfamily A (CYP3A) isoenzymes are ineligible
Use of any medication or substances that are strong inhibitors or inducers of CYP3A isoenzymes.
Receiving any medications or substances that are inducers of CYP3A4; use of inducers are prohibited =< 7 days prior to registration
Patients receiving certain medications and/or substances that are prohibited within stated wash-out periods
The eligibility of patients taking medications that are potent inducers or inhibitors of the cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) liver enzyme will be determined following a review of their case by the principal investigator; every effort should be made to switch patients taking such agents or substances to other medications; any identified agent needs to be stopped at least 2 weeks prior to study registration
Patients receiving any medications or substances that are inhibitors or inducers of cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP 450 3A4) are ineligible
Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4
Patients receiving any medications or substances that are inhibitors or inducers of CYP450 enzyme(s) are ineligible
PHASE II: Participants receiving any medications or substances that are strong inhibitors of CYP3A4 are ineligible
Receiving any medications or substances that are inducers of CYP3A4\r\n* Use of inducers is prohibited =< 12 days prior to registration
Patients receiving any medications or substances that are strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) complex are ineligible
Patients receiving any medications or substances that are strong inhibitors or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) are ineligible; an exception will be made for patients who are on ritonavir-based highly active antiretroviral therapy, in which case the starting dose of sunitinib will be modified; every effort should be made to switch patients taking such agents or substances to other medications
Participants receiving any medications or substances that are strong inhibitors or inducers of CYP3A isoenzymes are ineligible
Prohibited medications, supplements and herbal medications:\r\n* Tetracycline and its derivatives (enhance the risk of retinoic acid toxicity)\r\n* Live vaccines\r\n* Vitamin A\r\n* St. Johnâ€™s wort\r\n* Dong quai: Herbal supplement, (Angelica sinensis)\r\n* Cytochrome P450 family 2 subfamily C member (CYP2C8) inhibitors: gemfibrozil, trimethoprim, thiazolinediones, montelukast, quercetin\r\n* CYP2C8 inducers: rifampicin\r\n* Patients receiving any medications or substances that are moderate and strong inhibitors of CYP2C8 or inducers of CYP2C8 are ineligible and can only be enrolled if these medications are discontinued
Patients receiving any medications or substances that are inhibitors or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP450 3A4) are ineligible
Patients who require concurrent treatment with any medications or substances that have significant proarrhythmic potential are ineligible
Strong CYP3A4 inhibitors are not permitted within 7 days before and during the study, and strong CYP3A4 inducers are not permitted within 12 days before and during the study; every effort should be made to switch patients taking such agents or substances to other medications 1 week prior to starting therapy, particularly patients with brain metastases who are taking enzyme-inducing anticonvulsant agents; patients who require potent CYP3A4 inducers or inhibitors and cannot switch medications must have their case reviewed by the coordinating center PI and may be enrolled only after discussion with and agreement from the coordinating center PI; eligibility of patients receiving any medications or substances known to affect or with the potential to affect the activity or pharmacokinetics (PK) of cediranib will be determined following review of their case by the coordinating center PI
As ketoconazole may inhibit paclitaxel metabolism, patients receiving ketoconazole for any treatment indication are ineligible; patients receiving any other medications or substances that are inhibitors or inducers of cytochrome P450 (CYP450) enzymes will be eligible; however, use all such medications or substances must be documented in the Case Report Forms
Patients receiving any medications or substances that are inhibitors or inducers of cytochrome P450 (CYP450) enzyme(s) are ineligible
Receiving any medications or substances that are inducers of CYP3A4
Participants receiving any medications or substances that are inhibitors or inducers of CYP3A4 are ineligible
Refusal or inability to discontinue medications or other substances (eg, foods or dietary supplements) that may affect 18F SKI-249380 metabolism; notably, as dasatinib metabolism is cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)-dependent, the metabolism of 18F SKI-249380 may be altered by inhibitors and inducers of cytochrome P450 isoenzyme CYP3A4; the acceptability of medications and other substances used by the patient will be determined by the study investigators
Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 and UGT are ineligible; the wash out period for such drugs is a minimum of 7 days or 5 half-lives whichever is shorter\r\n* Note: If a medication is incorrectly documented as prohibited in this protocol, documentation from the site pharmacist to the contrary will be acceptable for the purposes of registration
